Literature DB >> 21245727

Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.

Henri G Franquelim1, Salvatore Chiantia, Ana Salomé Veiga, Nuno C Santos, Petra Schwille, Miguel A R B Castanho.   

Abstract

OBJECTIVES: 2F5 and 4E10 are two broadly neutralizing monoclonal antibodies (mAbs) targeting the membrane proximal external region (MPER) of HIV-1 gp41 envelope protein. This region, which contacts the viral membrane, is highly conserved and has been regarded as a promising target for vaccine development. We aimed to clarify the basis of 2F5 and 4E10 molecular interactions with epitope cores in MPER and lipid bilayers.
DESIGN: Microscopy-based approaches were used to infer and quantify the effects of both mAbs on membranes, in the presence and absence of the epitope cores. Supported lipid bilayers (SLBs), with and without phase separation, were used as membrane models. Fluorescent-labeled and nonlabeled MPER-derived peptides containing both 2F5 and 4E10 epitopes were used.
METHODS: mAbs 2F5 and 4E10 membrane interactions, in the presence or absence of MPER-derived peptides, were evaluated by combined atomic force and confocal microscopies.
RESULTS: Both mAbs form lipid-segregated aggregates on SLBs and do not induce other significant membrane perturbations. Furthermore, the affinity of MPER toward membranes is differently affected by both mAbs and correlates with the mAbs-epitope core lipid interactions. 2F5 is able to dock the MPER peptide on the membrane, whereas 4E10 extracts the MPER from the lipid bilayer.
CONCLUSION: The results reveal the molecular details underneath 2F5/4E10 membrane-epitope binding and a model is proposed to explain the differential mAbs neutralization efficacies, which relates to the exposure of the epitopes in the lipid bilayers and the role of the lipids in mAb-epitope binding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245727     DOI: 10.1097/QAD.0b013e328342ff11

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

Review 1.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 2.  Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors:  F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

3.  Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.

Authors:  Ramesh Rathinakumar; Moumita Dutta; Ping Zhu; Welkin E Johnson; Kenneth H Roux
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure.

Authors:  Marcelo T Augusto; Axel Hollmann; Miguel A R B Castanho; Matteo Porotto; Antonello Pessi; Nuno C Santos
Journal:  J Antimicrob Chemother       Date:  2014-01-23       Impact factor: 5.790

5.  HIV-1 antibodies and vaccine antigen selectively interact with lipid domains.

Authors:  Gregory J Hardy; Gene C Wong; Rahul Nayak; Kara Anasti; Michael Hirtz; Joseph G Shapter; S Munir Alam; Stefan Zauscher
Journal:  Biochim Biophys Acta       Date:  2014-07-11

6.  Biomimetic supported lipid bilayers with high cholesterol content formed by α-helical peptide-induced vesicle fusion.

Authors:  Gregory J Hardy; Rahul Nayak; S Munir Alam; Joseph G Shapter; Frank Heinrich; Stefan Zauscher
Journal:  J Mater Chem       Date:  2012-08-28

7.  Model cell membranes: Techniques to form complex biomimetic supported lipid bilayers via vesicle fusion.

Authors:  Gregory J Hardy; Rahul Nayak; Stefan Zauscher
Journal:  Curr Opin Colloid Interface Sci       Date:  2013-10-01       Impact factor: 6.448

8.  Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Authors:  Lianxing Liu; Yanling Hao; Zhenwu Luo; Yang Huang; Xintao Hu; Ying Liu; Yiming Shao
Journal:  Vaccine       Date:  2012-05-02       Impact factor: 3.641

Review 9.  Plant made anti-HIV microbicides--a field of opportunity.

Authors:  Hester C T Lotter-Stark; Edward P Rybicki; Rachel K Chikwamba
Journal:  Biotechnol Adv       Date:  2012-06-28       Impact factor: 14.227

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.